Swedish Orphan Biovitrum AB (publ) (http://www.sobi.com/) (Sobi®) today announced its report
for the first quarter of 2023

•           Total revenue SEK 5,239 M (4,925), +6 per cent, -2 per cent at constant exchange rates (CER).[i]

•           Haematology revenue SEK 2,815 M (2,499), +5 per cent at CER of which Elocta® SEK 1,196 M (1,024), +9 per cent at CER; Alprolix® SEK 514 M (419), +16 per cent at CER; Doptelet® SEK 475 M (593), -28 per cent at CER and Aspaveli®/Empaveli® SEK 95 M (4)

•           Immunology revenue SEK 2,151 M (2,119), -9 per cent at CER of which Kineret® SEK 533 M (645), -24 per cent at CER; Synagis® SEK 1,398 M (1,286), -3 per cent at CER and Gamifant® SEK 219 M (189), +5 per cent at CER

•           EBITA[i] SEK 2,121 M (1,290); EBITA margin[i] 40 per cent (26). EBIT SEK 1,495 M (776)

•           Earnings per share (EPS) before dilution SEK 3.60 (1.84), EPS adjusted before dilution[i] SEK 3.60 (3.67). Cash flow from operating activities SEK 1,983 M (1,644)

•           SEL-212 CRG positive phase 3 studies topline data readout

•           Efanesoctocog alfa regulatory approval in the US (by Sanofi) and positive XTEND-Kids phase 3 study topline data readout

•           Nirsevimab economics simplified through a new royalty agreement with Sanofi and the termination of the participation agreement with AstraZeneca

•          Revenue is anticipated to grow by a low-to-mid single-digit percentage at CER

•          EBITA margin adjusted[2] is anticipated to be at a low 30s percentage of revenue

Financial summary

[][][][][][]
Q1      Q1     FY
SEK M 2023     2022     Change  2022
Total revenue 5,239    4,925     6%  18,790
Gross profit 4,172    3,409     22%  14,014
Gross margin[i]  80%       69%   75%
EBITA[i] 2,121    1,290     64%  5,930
EBITA adjusted[i,ii] 2,121    1,951     9%  6,605
EBITA margin[i]  40%     26%  32%
EBITA margin  40%     40%  35%
adjusted[i,ii]
Profit for the period 1,067     543     96%  2,638
EPS, before dilution, 3.60    1.84     96%  8.92
SEK
EPS, before dilution, 3.60    3.67     -2%  10.77
SEK adjusted[i,ii   ]

i. Alternative Performance Measures.
ii. Items affecting comparability (IAC) in 2022.

1 The outlook excludes Sobi's right to royalty on net sales of nirsevimab in the US

2   Excluding IAC.

Investors, analysts and media are invited to participate in a conference call which will include a presentation of the results and a Q&A session at 14:00 CEST.

The presentation can be followed live here (https://linkprotect.cudasvc.com/url?a=https%3a%2f%2fonlinexperiences.com%2fLaunch%2fQReg%2fShowUUID%3d03202595-C004-487A-9D35-2F1938A67C99&c=E,1,bWMRJRllgwh6kpCCfsTkWIgcKLFG5whfxtIhOLik-kowVKxpZtsOhFRsLgYbDg0gpMuxtC7ku7vVczP5wyUTR4J5gzZxkS7gAzNDciX9Ln3fUJG0DP8res38rymb&typo=1) or afterwards on sobi.com (https://www.sobi.com/en/investors). The slides will be made available on sobi.com (https://www.sobi.com/en/investors) prior to the conference call.

To participate in the conference call, please use the following dial-in details:

Sweden: +46 8 5051 0031

United Kingdom: +44 207 107 06 13

United States: +1 631 570 56 13

For other countries, please get details here (https://services3.choruscall.ch/NUMBERS/Attended_Dial_In_Numbers.pdf)

Sobi®

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,600 employees across Europe, North America, the Middle East, Asia and Australia. In 2022, revenue amounted to SEK 18.8 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com, LinkedIn (https://www.linkedin.com/company/sobi/) and YouTube (https://www.youtube.com/c/Sobi-Pharma).

Contacts

For details on how to contact the Sobi Investor Relations Team, please click here (https://www.sobi.com/en/ir-contacts). For Sobi Media contacts, click here (https://www.sobi.com/en/media).

This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on 27 April 2023 at 08:00 CET.

Camilla Sandström

Interim Head of IR, External Communication and Sustainability